CNS Pharmaceuticals, Inc. (CNSP)

NASDAQ: CNSP · IEX Real-Time Price · USD

1.260

-0.160 (-11.27%)

At close: Jul 2, 2024, 4:00 PM

1.280

+0.020 (1.59%)

After-hours: Jul 2, 2024, 7:56 PM EDT

CNS Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	4.77	5.97	4.68	4.39	1.98	Upgrade
Research & Development	14.1	9.3	9.81	5.06	1.85	Upgrade
Operating Expenses	18.87	15.27	14.49	9.45	3.83	Upgrade
Operating Income	-18.87	-15.27	-14.49	-9.45	-3.83	Upgrade
Interest Expense / Income	0.01	0.01	0.01	0	0.03	Upgrade
Other Expense / Income	-0.03	-	-	-	0.02	Upgrade
Pretax Income	-18.85	-15.27	-14.5	-9.46	-3.88	Upgrade
Net Income	-18.85	-15.27	-14.5	-9.46	-3.88	Upgrade
Shares Outstanding (Basic)	0	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	0	0	0	0	0	Upgrade
Shares Change	176.66%	55.02%	58.58%	21.76%	29.86%	Upgrade
EPS (Basic)	-250.00	-561.00	-825.00	-855.01	-420.00	Upgrade
EPS (Diluted)	-250.00	-561.00	-825.00	-855.01	-420.00	Upgrade
Free Cash Flow	-14.14	-10.56	-13.54	-7.34	-3.57	Upgrade
Free Cash Flow Per Share	-187.72	-387.82	-770.91	-662.16	-392.77	Upgrade
EBITDA	-18.83	-15.26	-14.47	-9.44	-3.85	Upgrade
Depreciation & Amortization	0	0.01	0.01	0.01	0	Upgrade
EBIT	-18.84	-15.27	-14.49	-9.45	-3.85	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).